Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata” or the "Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other ...
If you’ve been diagnosed with breast cancer, you’re likely wondering if it has spread and if so, how far? Your doctor can ...
Researchers present an overview of treatment and management strategies for patients with HR+/HER2+ breast cancer, including common adverse effects.
In HR+/HER- early breast cancer, the DFS benefits of adjuvant ribociclib plus NSAI treatment compared to NSAI alone persisted even a year after treatment completion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback